SGLT2 inhibitors may be a useful adjunct therapy to reduce anemia risk in patients with type 2 diabetes and early CKD. Anemia risk is lower among patients receiving SGLT2 inhibitors (SGLT2i) compared ...

Sotagliflozin, a dual sodium-glucose cotransporter 1 and 2 inhibitor, rapidly improves hemoglobin levels in patients with type 2 diabetes (T2D) and moderate to severe chronic kidney disease (CKD), ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Let's start with what causes anemia of ...

Nonetheless, the number of CKD-related anemia cases continues to increase, due to population growth, aging, and other factors. Anemia cases attributable to chronic kidney disease (CKD) continue to ...

SGLT2 inhibitors significantly improve hemoglobin and hematocrit levels in CKD patients, enhancing anemia management. The KDIGO 2024 guideline endorses SGLT2 inhibitors for CKD patients, highlighting ...

The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment ...

The FDA approved vadadustat (Vafseo) for chronic kidney disease (CKD)-related anemia in adults who have been on dialysis for at least 3 months, developer Akebia Therapeutics announced on Wednesday.

Modus Therapeutics Holding AB has announced that the first patient has been dosed in part 2 of its ongoing phase 2a clinical study evaluating sevuparin for the treatment of chronic kidney disease (CKD ...